Physician profile
Anne E Reitz
NPI 1376715185
$4,947.54
in general payments reported to CMS, 2019-2025
35 companies · $944 in 2025
The $944 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,519 · 2022: $788 · 2023: $650 · 2024: $1,046 · 2025: $944.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,590 · Long Term Medical Supply Or Device Loan: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,589.72 |
| Long Term Medical Supply Or Device Loan | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $978.71 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $528.26 | 2021-2025 | |
| Novo Nordisk INC | $411.93 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $407.28 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $339.67 | 2021-2025 | Trelegy Ellipta |
| Axsome Therapeutics, INC. | $319.64 | 2023-2025 | Auvelity |
| Biohaven Pharmaceuticals, INC. | $227.04 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.29 | 2021-2023 | Jardiance, Stiolto Respimat |
| Amarin Pharma, INC. | $128.25 | 2021-2022 | |
| Ucb, INC. | $124.20 | 2024 | Nayzilam |
| Dexcom, INC. | $119.41 | 2021-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $115.23 | 2021-2025 | Freestyle Insulinx, Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $112.01 | 2021-2025 | |
| Therapeuticsmd, INC. | $100.00 | 2021 | |
| Exact Sciences Corporation | $95.64 | 2023-2025 | Cologuard Collection Kit |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $89.30 | 2022-2024 | Gvoke Hypopen |
| Astellas Pharma US INC | $82.10 | 2021-2024 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $73.42 | 2021-2022 | |
| Amgen INC. | $71.52 | 2021-2025 | Evenity |
| Janssen Pharmaceuticals, INC | $67.54 | 2021-2023 | Xarelto |
| Corium, LLC | $59.59 | 2023-2025 | Azstarys, Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $53.58 | 2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $36.49 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.99 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $31.13 | 2024-2025 | Voquezna |
| Philips North America LLC | $20.23 | 2025 | Extended Holter |
| Lundbeck LLC | $18.95 | 2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $18.29 | 2021 | |
| Sanofi-Aventis U.S. LLC | $16.71 | 2021 | |
| Bausch Health US, LLC | $16.37 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.48 | 2021 | |
| Novartis Pharmaceuticals Corporation | $13.20 | 2022 | |
| Alexion Pharmaceuticals, INC. | $13.12 | 2024 | Koselugo |
| Organogenesis INC. | $12.92 | 2021 | |
| Merck Sharp & Dohme LLC | $12.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Reitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.